For previous year please see:
US FluView - Weekly Surveillance Flu report 2022/2023 season - for trend analysis
Weekly U.S. Influenza Surveillance Report
Print
Updated October 13, 2023
Key Updates for Week 40, ending October 7, 2023
Seasonal influenza activity remains low nationally. Viruses
Clinical Lab 1.1%
(Trend
)
positive for influenza
this week
Public Health Lab
The most frequently reported influenza viruses this week were influenza A(H1N1).
Virus Characterization
Genetic and antigenic characterization are summarized in this report. Illness
Outpatient Respiratory Illness 2.2%
(Trend)
of visits to a health care provider this week were for respiratory illness
(below baseline).
Outpatient Respiratory Illness: Activity Map
This week 1 jurisdiction experienced moderate activity and 0 jurisdictions experienced high or very activity.
FluSurv-NET 0.1 per 100,000
cumulative hospitalization rate.
NHSN Hospitalizations 1,127
(Trend
)
patients admitted to hospitals with influenza
this week.
NCHS Mortality 0.05%
(Trend)
of deaths attributed influenza this week.
Pediatric Deaths 1
death that occurred during the 2022-2023 season was reported this week.
All data are preliminary and may change as more reports are received.
Directional arrows indicate changes between the current week and the previous week. Additional information on the arrows can be found at the bottom of this page.
A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.
Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.
Key Points
Nationally, the percentage of specimens testing positive for influenza in clinical laboratories remained stable (change of <0.5 percentage points) compared to the previous week. In Regions 4 and 9, this percentage increased compared to the previous week. For regional and state level data and age group distribution, please visit FluView Interactive. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses. Clinical Laboratories
The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza virus) are used to monitor whether influenza activity is increasing or decreasing.
View Chart Data | View Full Screen Public Health Laboratories
The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating influenza viruses that belong to each influenza subtype/lineage.
View Chart Data | View Full Screen
Additional virologic surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data Influenza Virus Characterization
CDC performs genetic and antigenic characterization of viruses submitted from U.S. state and local public health laboratories according to the Right Size Roadmap submission guidance. These data are used to compare how similar the currently circulating influenza viruses are to the reference viruses representing viruses contained in the current influenza vaccines. The data are also used to monitor evolutionary changes that continually occur in influenza viruses circulating in humans. CDC also tests susceptibility of circulating influenza viruses to antiviral medications including the neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir) and the PA endonuclease inhibitor baloxavir.
CDC has genetically characterized 435 influenza viruses collected since May 1, 2023.
CDC antigenically characterizes influenza viruses by hemagglutination inhibition (HI) (H1N1pdm09, H3N2, B/Victoria, and B/Yamagata viruses) or neutralization-based HINT (H3N2 viruses) using antisera that ferrets make after being infected with reference viruses representing the 2023-2024 Northern Hemisphere recommended cell or recombinant-based vaccine viruses. Antigenic differences between viruses are determined by comparing how well the antibodies made against the vaccine reference viruses recognize the circulating viruses that have been grown in cell culture. Ferret antisera are useful because antibodies raised against a particular virus can often recognize small changes in the surface proteins of other viruses. In HI assays, viruses with similar antigenic properties have antibody titer differences of less than or equal to 4-fold when compared to the reference (vaccine) virus. In HINT, viruses with similar antigenic properties have antibody neutralization titer differences of less than or equal to 8-fold. Viruses selected for antigenic characterization are a subset representing the genetic changes in the surface proteins seen in genetically characterized viruses.
Influenza A Viruses
The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for respiratory illness referred to as influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza virus, SARS-CoV-2, and RSV. It is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is providing integrated information about COVID-19, influenza and RSV activity on a website that is updated weekly. Information about other respiratory virus activity can be found on CDC’s National Respiratory and Enteric Virus Surveillance System (NREVSS) website. Outpatient Respiratory Illness Visits
Nationwide during week 40, 2.2% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. This has remained stable (change of ≤ 0.1 percentage points) compared to week 39 and is below the national baseline of 2.9%. All 10 HHS regions are below their respective baselines. Region 9 increased, Region 2 decreased, and all other regions remained stable compared to week 39. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.
Outpatient Respiratory Illness Visits by Age Group
About 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.
The percentage of visits for respiratory illness reported in ILINet increased for two age groups (0-4 years, 5-24 years) and remained stable (change of ≤ 0.1 percentage point) for three age groups (25-49 years, 50-64 years, and 65+ years) in week 40 compared to week 39.
View Chart Data | View Full Screen Outpatient Respiratory Illness Activity Map
Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
*Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.
Additional information about medically attended visits for ILI for current and past seasons:
Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map Hospitalization Surveillance
FluSurv-NET
The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. As data are received each week, prior case counts and rates are updated accordingly.
A total of 37 laboratory-confirmed influenza-associated hospitalizations were reported by FluSurv-NET sites between October 1, 2023, and October 7, 2023. The weekly hospitalization rate observed in week 40 was 0.1 per 100,000 population.
When examining rates by age, the hospitalization rate per 100,000 population among adults aged 18 years and older was 0.1, and among children aged 0-17 years, the hospitalization rate per 100,000 population was also 0.1.
View Full Screen
Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:
Surveillance Methods |FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics | RESP-NET Interactive National Healthcare Safety Network (NHSN) Hospitalization Surveillance
Hospitals report to NHSN the number of patients admitted with laboratory-confirmed influenza. During week 40, 1,127 patients with laboratory-confirmed influenza were admitted to a hospital. The number of patients admitted to a hospital with laboratory-confirmed influenza slightly increased compared to week 39 (increase of >5%). Regions 1, 4, 5, 7, and 10 slightly increased and all other regions remained stable or decreased.
View Chart Data | View Full Screen
Additional NHSN Hospitalization Surveillance information:
Surveillance Methods | Additional Data | FluView Interactive Mortality Surveillance
National Center for Health Statistics (NCHS) Mortality Surveillance
Based on NCHS mortality surveillance data available on October 12, 2023, 0.05% of the deaths that occurred during the week ending October 7, 2023 (week 40), were due to influenza. This percentage remained stable (≤ 0.1 percentage point change) compared to week 39. The data presented are preliminary and may change as more data are received and processed.
The percentages of deaths due to pneumonia and influenza (P&I) and due to pneumonia, influenza, or COVID-19 (PIC) will no longer be displayed in FluView but are available in FluView Interactive.
Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive Influenza-Associated Pediatric Mortality
No influenza-associated pediatric deaths occurring during the 2023-2024 season have been reported to CDC.
One influenza-associated pediatric death occurring during the 2022-2023 season was reported to CDC during week 40. The death was associated with an influenza A(H3) virus and occurred during week 52 (the week ending December 31, 2022). A total of 178 influenza-associated pediatric deaths that occurred during the 2022-2023 season have been reported to CDC.
Additional pediatric mortality surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive Trend Indicators
Increasing:
Decreasing:
Stable:
Indicators Status by System
Clinical Labs: Up or down arrows indicate a change of greater than or equal to 0.5 percentage points in the percent of specimens positive for influenza compared to the previous week.
Outpatient Respiratory Illness (ILINet): Up or down arrows indicate a change of greater than 0.1 percentage points in the percent of visits due to respiratory illness (ILI) compared to the previous week.
NHSN Hospitalizations: Up or down arrows indicate change of greater than or equal to 5% of the number of patients admitted with laboratory-confirmed influenza compared to the previous week.
NCHS Mortality: Up or down arrows indicate change of greater than 0.3 percentage points of the percent of deaths due to PIC compared to the previous week. Reference Footnotes
[SUP]1[/SUP]U.S. Influenza Surveillance: Purpose and Methods (2023 Oct). Centers for Disease Control and Prevention. https://www.cdc.gov/flu/weekly/overview.htm#ILINet.
[SUP]2[/SUP]Grohskopf LA, Blanton LH, Ferdinands JM, Chung JR, Broder KR, Talbot HK. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023–24 Influenza Season. MMWR Recomm Rep 2023;72(No. RR-2):1–25. DOI: http://dx.doi.org/10.15585/mmwr.rr7202a1
[SUP]3[/SUP]Influenza Antiviral Medications: Summary for Clinicians (2023 Sept). Centers for Disease Control and Prevention. https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm.
https://www.cdc.gov/flu/weekly/index.htm
US FluView - Weekly Surveillance Flu report 2022/2023 season - for trend analysis
Weekly U.S. Influenza Surveillance Report
Updated October 13, 2023
Key Updates for Week 40, ending October 7, 2023
Seasonal influenza activity remains low nationally. Viruses
Clinical Lab 1.1%
(Trend
)positive for influenza
this week
Public Health Lab
The most frequently reported influenza viruses this week were influenza A(H1N1).
Virus Characterization
Genetic and antigenic characterization are summarized in this report. Illness
Outpatient Respiratory Illness 2.2%
(Trend
)of visits to a health care provider this week were for respiratory illness
(below baseline).
Outpatient Respiratory Illness: Activity Map
This week 1 jurisdiction experienced moderate activity and 0 jurisdictions experienced high or very activity.
FluSurv-NET 0.1 per 100,000
cumulative hospitalization rate.
NHSN Hospitalizations 1,127
(Trend
)patients admitted to hospitals with influenza
this week.
NCHS Mortality 0.05%
(Trend
)of deaths attributed influenza this week.
Pediatric Deaths 1
death that occurred during the 2022-2023 season was reported this week.
All data are preliminary and may change as more reports are received.
Directional arrows indicate changes between the current week and the previous week. Additional information on the arrows can be found at the bottom of this page.
A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.
Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.
Key Points
- Seasonal influenza activity remains low nationally.
- Nationally, outpatient respiratory illness is below baseline[SUP]1[/SUP], and all 10 HHS regions are below their respective baselines.
- The number of flu hospital admissions remains low.
- During week 40, 50 (86.2%) of the 58 viruses reported by public health laboratories were influenza A and 8 (13.8%) were influenza B. Of the 33 influenza A viruses subtyped during week 40; 30 were influenza A(H1N1) and 3 were A(H3N2).
- One influenza-associated pediatric death that occurred during the 2022-2023 season was reported this week.
- CDC recommends that everyone ages 6 months and older get an annual flu vaccine, ideally by the end of October.[SUP]2[/SUP]
- There are also prescription flu antiviral drugs that can be used to treat flu illness; those need to be started as early as possible.[SUP]3[/SUP]
- Influenza virus is one of several viruses that contribute to respiratory disease activity. CDC is providing updated, integrated information about COVID-19, influenza, and RSV activity on a weekly basis.
Nationally, the percentage of specimens testing positive for influenza in clinical laboratories remained stable (change of <0.5 percentage points) compared to the previous week. In Regions 4 and 9, this percentage increased compared to the previous week. For regional and state level data and age group distribution, please visit FluView Interactive. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses. Clinical Laboratories
The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza virus) are used to monitor whether influenza activity is increasing or decreasing.
| No. of specimens tested | 47,296 | 53,556 |
| No. of positive specimens (%) | 530 (1.1%) | 492 (0.9%) |
| Positive specimens by type | ||
| Influenza A | 320 (60.4%) | 315 (64.0%) |
| Influenza B | 210 (39.6%) | 177 (36.0%) |
View Chart Data | View Full Screen Public Health Laboratories
The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating influenza viruses that belong to each influenza subtype/lineage.
| No. of specimens tested | 2,246 | 3,011 |
| No. of positive specimens | 58 | 152 |
| Positive specimens by type/subtype | ||
| Influenza A | 50 (86.2%) | 126 (82.9%) |
| Subtyping Performed | 33 (66.0%) | 116 (92.1%) |
| (H1N1)pdm09 | 30 (90.9%) | 108 (93.1%) |
| H3N2 | 3 (9.1%) | 8 (6.9%) |
| H3N2v | 0 (0%) | 0 (0%) |
| Subtyping not performed | 17 (34.0%) | 10 (7.9%) |
| Influenza B | 8 (13.8%) | 26 (17.1%) |
| Lineage testing performed | 2 (25.0%) | 18 (69.2%) |
| Yamagata lineage | 0 (0%) | 0 (0%) |
| Victoria lineage | 2 (100%) | 18 (100%) |
| Lineage not performed | 6 (75.0%) | 8 (30.8%) |
View Chart Data | View Full Screen
Additional virologic surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data Influenza Virus Characterization
CDC performs genetic and antigenic characterization of viruses submitted from U.S. state and local public health laboratories according to the Right Size Roadmap submission guidance. These data are used to compare how similar the currently circulating influenza viruses are to the reference viruses representing viruses contained in the current influenza vaccines. The data are also used to monitor evolutionary changes that continually occur in influenza viruses circulating in humans. CDC also tests susceptibility of circulating influenza viruses to antiviral medications including the neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir) and the PA endonuclease inhibitor baloxavir.
CDC has genetically characterized 435 influenza viruses collected since May 1, 2023.
| A/H1 | 214 | ||||
| 6B.1A.5a | 214 (100%) | 2a | 80 (37.4%) | ||
| 2a.1 | 134 (62.6%) | ||||
| A/H3 | 24 | ||||
| 3C.2a1b.2a | 24 (100%) | 2a.3a | 2 (8.3%) | ||
| 2a.3a.1 | 21 (87.5%) | ||||
| 2b | 1 (4.2%) | ||||
| B/Victoria | 197 | ||||
| V1A | 197 (100%) | 3a.2 | 197 (100%) | ||
| B/Yamagata | 0 | ||||
| Y3 | 0 | Y3 | 0 (0%) |
Influenza A Viruses
- A (H1N1)pdm09: Sixty-eight A(H1N1)pdm09 viruses were antigenically characterized by HI, and all were well-recognized (reacting at titers that were within 4-fold of the homologous virus titer) by ferret antisera to cell-grown A/Wisconsin/67/2022-like reference viruses representing the A(H1N1)pdm09 component for the cell- and recombinant-based influenza vaccines.
- A (H3N2): Fourteen A(H3N2) viruses were antigenically characterized by HI or HINT, and all were well-recognized (reacting at titers that were within 4-fold of the homologous virus) by ferret antisera to cell-grown A/Darwin/6/2021-like reference viruses representing the A(H3N2) component for the cell- and recombinant-based influenza vaccines.
- B/Victoria: Forty-five influenza B/Victoria-lineage virus were antigenically characterized by HI, and all were well-recognized (reacting at titers that were within 4-fold of the homologous virus titer) by ferret antisera to cell-grown B/Austria/1359417/2021-like reference viruses representing the B/Victoria component for the cell- and recombinant-based influenza vaccines.
- B/Yamagata: No influenza B/Yamagata-lineage viruses were available for antigenic characterization.
The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for respiratory illness referred to as influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza virus, SARS-CoV-2, and RSV. It is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is providing integrated information about COVID-19, influenza and RSV activity on a website that is updated weekly. Information about other respiratory virus activity can be found on CDC’s National Respiratory and Enteric Virus Surveillance System (NREVSS) website. Outpatient Respiratory Illness Visits
Nationwide during week 40, 2.2% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. This has remained stable (change of ≤ 0.1 percentage points) compared to week 39 and is below the national baseline of 2.9%. All 10 HHS regions are below their respective baselines. Region 9 increased, Region 2 decreased, and all other regions remained stable compared to week 39. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.
Outpatient Respiratory Illness Visits by Age Group
About 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.
The percentage of visits for respiratory illness reported in ILINet increased for two age groups (0-4 years, 5-24 years) and remained stable (change of ≤ 0.1 percentage point) for three age groups (25-49 years, 50-64 years, and 65+ years) in week 40 compared to week 39.
View Chart Data | View Full Screen Outpatient Respiratory Illness Activity Map
Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
| Week 40 (Week ending Oct. 7, 2023) | Week 39 (Week ending Sept. 30, 2023) | Week 40 (Week ending Oct. 7, 2023) | Week 39 (Week ending Sept. 7, 2023) | |
| Very High | 0 | 0 | 0 | 2 |
| High | 0 | 3 | 3 | 14 |
| Moderate | 1 | 2 | 9 | 26 |
| Low | 6 | 6 | 57 | 80 |
| Minimal | 47 | 44 | 610 | 554 |
| Insufficient Data | 1 | 0 | 250 | 253 |
*Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.
Additional information about medically attended visits for ILI for current and past seasons:
Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map Hospitalization Surveillance
FluSurv-NET
The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. As data are received each week, prior case counts and rates are updated accordingly.
A total of 37 laboratory-confirmed influenza-associated hospitalizations were reported by FluSurv-NET sites between October 1, 2023, and October 7, 2023. The weekly hospitalization rate observed in week 40 was 0.1 per 100,000 population.
When examining rates by age, the hospitalization rate per 100,000 population among adults aged 18 years and older was 0.1, and among children aged 0-17 years, the hospitalization rate per 100,000 population was also 0.1.
View Full Screen
Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:
Surveillance Methods |FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics | RESP-NET Interactive National Healthcare Safety Network (NHSN) Hospitalization Surveillance
Hospitals report to NHSN the number of patients admitted with laboratory-confirmed influenza. During week 40, 1,127 patients with laboratory-confirmed influenza were admitted to a hospital. The number of patients admitted to a hospital with laboratory-confirmed influenza slightly increased compared to week 39 (increase of >5%). Regions 1, 4, 5, 7, and 10 slightly increased and all other regions remained stable or decreased.
View Chart Data | View Full Screen
Additional NHSN Hospitalization Surveillance information:
Surveillance Methods | Additional Data | FluView Interactive Mortality Surveillance
National Center for Health Statistics (NCHS) Mortality Surveillance
Based on NCHS mortality surveillance data available on October 12, 2023, 0.05% of the deaths that occurred during the week ending October 7, 2023 (week 40), were due to influenza. This percentage remained stable (≤ 0.1 percentage point change) compared to week 39. The data presented are preliminary and may change as more data are received and processed.
The percentages of deaths due to pneumonia and influenza (P&I) and due to pneumonia, influenza, or COVID-19 (PIC) will no longer be displayed in FluView but are available in FluView Interactive.
Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive Influenza-Associated Pediatric Mortality
No influenza-associated pediatric deaths occurring during the 2023-2024 season have been reported to CDC.
One influenza-associated pediatric death occurring during the 2022-2023 season was reported to CDC during week 40. The death was associated with an influenza A(H3) virus and occurred during week 52 (the week ending December 31, 2022). A total of 178 influenza-associated pediatric deaths that occurred during the 2022-2023 season have been reported to CDC.
Additional pediatric mortality surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive Trend Indicators
Increasing:
Decreasing:
Stable:
Clinical Labs: Up or down arrows indicate a change of greater than or equal to 0.5 percentage points in the percent of specimens positive for influenza compared to the previous week.
Outpatient Respiratory Illness (ILINet): Up or down arrows indicate a change of greater than 0.1 percentage points in the percent of visits due to respiratory illness (ILI) compared to the previous week.
NHSN Hospitalizations: Up or down arrows indicate change of greater than or equal to 5% of the number of patients admitted with laboratory-confirmed influenza compared to the previous week.
NCHS Mortality: Up or down arrows indicate change of greater than 0.3 percentage points of the percent of deaths due to PIC compared to the previous week. Reference Footnotes
[SUP]1[/SUP]U.S. Influenza Surveillance: Purpose and Methods (2023 Oct). Centers for Disease Control and Prevention. https://www.cdc.gov/flu/weekly/overview.htm#ILINet.
[SUP]2[/SUP]Grohskopf LA, Blanton LH, Ferdinands JM, Chung JR, Broder KR, Talbot HK. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023–24 Influenza Season. MMWR Recomm Rep 2023;72(No. RR-2):1–25. DOI: http://dx.doi.org/10.15585/mmwr.rr7202a1
[SUP]3[/SUP]Influenza Antiviral Medications: Summary for Clinicians (2023 Sept). Centers for Disease Control and Prevention. https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm.
https://www.cdc.gov/flu/weekly/index.htm
Last edited by a moderator:
